Spider venomics: Implications for drug discovery

Future Medicinal Chemistry

Volumn 6, Issue 15, 2014, Pages 1699-1714

  Pineda, Sandy S ^a   Undheim, Eivind A B ^a   Rupasinghe, Darshani B ^a   Ikonomopoulou, Maria P ^a   King, Glenn F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACID SENSING ION CHANNEL; ANTINEOPLASTIC AGENT; PEPTIDE; PURINERGIC P2X RECEPTOR ANTAGONIST; PUROTOXIN 1; SODIUM CHANNEL; SPIDER VENOM; SPIDER VENOM PEPTIDE; UNCLASSIFIED DRUG; CALCIUM CHANNEL; ISOPROTEIN; RECOMBINANT PROTEIN; VOLTAGE GATED SODIUM CHANNEL;

ANTINEOPLASTIC ACTIVITY; BIOMICS; CEREBROVASCULAR ACCIDENT; DISULFIDE BOND; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; NONHUMAN; PAIN; PHARMACOPHORE; PREDATOR PREY INTERACTION; PROTEIN DEGRADATION; PROTEOMICS; REVIEW; SPIDER; STRUCTURE ACTIVITY RELATION; TRANSCRIPTOMICS; VENOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; METABOLISM;

ANIMALS; CALCIUM CHANNELS; DRUG DISCOVERY; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; SPIDER VENOMS; SPIDERS; STRUCTURE-ACTIVITY RELATIONSHIP; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84911922472     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/FMC.14.103     Document Type: Review

References (144)

1. Fry BG, Roelants K, Champagne DE et al. The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu. Rev. Genomics Hum. Genet. 10(1), 483-511 (2009).
2. von Reumont BM, Blanke A, Richter S, Alvarez F, Bleidorn C, Jenner RA. The first venomous crustacean revealed by transcriptomics and functional morphology: remipede venom glands express a unique toxin cocktail dominated by enzymes and a neurotoxin. Mol. Biol. Evol. 31(1), 48-58 (2014).
3. Berkov A, Rodriguez N, Centeno P. Convergent evolution in the antennae of a cerambycid beetle, Onychocerus albitarsis, and the sting of a scorpion. Naturwissenschaften 95(3), 257-261 (2008).
4. Platnick NI. Advances in spider taxonomy, 1992-1995: with redescriptions 1940-1980. New York Entomological Society & The American Museum of Natural History, NY, USA (2011).Updated information and statistics available at www.wsc.nmbe.ch/statistics/
5. Escoubas P, Bosmans F. Spider peptide toxins as leads for drug development. Expert Opin. Drug Discov. 2(6), 823-835 (2007).
6. King GF, Hardy MC. Spider-venom peptides: structure, pharmacology, and potential for control of insect pests. Annu. Rev. Entomol. 58, 475-496 (2013).
7. Rash LD, Hodgson WC. Pharmacology and biochemistry of spider venoms. Toxicon 40(3), 225-254 (2002).
8. King GF. The wonderful world of spiders: preface to the special Toxicon issue on spider venoms. Toxicon 43(5), 471-475 (2004).
9. Escoubas P, Sollod B, King GF. Venom landscapes: mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 47(6), 650-663 (2006).
10. Kuhn-Nentwig L, Stöcklin R, Nentwig W. Venom composition and strategies in spiders: is everything possible? Adv. Insect Physiol. 40, 1-86 (2011).
11. King GF. Venoms to drugs: translating venom peptides into therapeutics. Aust. Biochem. 44(3), 13-15 (2013).
12. King GF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin. Biol. Ther. 11(11), 1469-1484 (2011).
13. Vetter I, Davis JL, Rash LD et al. Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 40, 15-28 (2011).
14. Escoubas P, Quinton L, Nicholson GM. Venomics: unravelling the complexity of animal venoms with mass spectrometry. J. Mass Spectrom. 43(3), 279-295 (2008).
15. Dutertre S, Jin AH, Kaas Q, Jones A, Alewood PF, Lewis RJ. Deep venomics reveals the mechanism for expanded peptide diversity in cone snail venom. Mol. Cell. Proteomics 12(2), 312-329 (2013).
16. Herzig V, Wood DLA, Newell F et al. ArachnoServer 2.0, an updated online resource for spider toxin sequences and structures Nucleic Acids Res. 39, D653-D657 (2011).
17. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS. A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides. Protein Sci. 3, 1833-1839 (1994).
18. King GF, Tedford HW, Maggio F. Structure and function of insecticidal neurotoxins from Australian funnel-web spiders. J. Toxicol. Toxin Rev. 21, 359-389 (2002).
19. Vassilevski AA, Kozlov SA, Grishin EV. Molecular diversity of spider venom. Biochemistry (Moscow) 74(13), 1505-1534 (2009).
20. Saez NJ, Senff S, Jensen JE et al. Spider-venom peptides as therapeutics. Toxins 2, 2851-2871 (2010).
21. Colgrave ML, Craik DJ. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43(20), 5965-5975 (2004).
22. Fletcher JI, Smith R, O'Donoghue SI et al. The structure of a novel insecticidal neurotoxin, ω-atracotoxin-HV1, from the venom of an Australian funnel web spider. Nat. Struct. Biol. 4, 559-566 (1997).
23. Perola E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J. Med. Chem. 53(7), 2986-2997 (2010).
24. Gui J, Liu B, Cao G et al. A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain. Curr. Biol. 24(5), 473-483 (2014).
25. Frontali N, Ceccarelli B, Gorio A et al. Purification from black widow spider venom of a protein factor causing the depletion of synaptic vesicles at neuromuscular junctions. J. Cell Biol. 68(3), 462-479 (1976).
26. Sheumack DD, Claassens R, Whiteley NM, Howden ME. Complete amino acid sequence of a new type of lethal neurotoxin from the venom of the funnel-web spider Atrax robustus. FEBS Lett. 181(1), 154-156 (1985).
27. Brown MR, Sheumack DD, Tyler MI, Howden ME. Amino acid sequence of versutoxin, a lethal neurotoxin from the venom of the funnel-web spider Atrax versutus. Biochem. J. 250(2), 401-405 (1988).
28. Kiyatkin NI, Dulubova IE, Chekhovskaya IA, Grishin EV. Cloning and structure of cDNA encoding α-latrotoxin from black widow spider venom. FEBS Lett. 270(1-2), 127-131 (1990).
29. Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc. Natl Acad. Sci. USA 85(23), 8998-9002 (1988).
30. Wang X-H, Connor M, Wilson D et al. Discovery and structure of a potent and highly specific blocker of insect calcium channels. J. Biol. Chem. 276(43), 40306-40312 (2001).
31. Diao JB, Lin Y, Tang JZ, Liang SP. cDNA sequence analysis of seven peptide toxins from the spider Selenocosmia huwena. Toxicon 42(7), 715-723 (2003).
32. Sollod BL, Wilson D, Zhaxybayeva O, Gogarten JP, Drinkwater R, King GF. Were arachnids the first to use combinatorial peptide libraries? Peptides 26(1), 131-139 (2005).
33. Kozlov S, Grishin EV. Classification of spider neurotoxins using structural motifs by primary structure features. Single residue distribution analysis and pattern analysis techniques. Toxicon 46(6), 672-686 (2005).
34. Chen J, Zhao L, Jiang L et al. Transcriptome analysis revealed novel possible venom components and cellular processes of the tarantula Chilobrachys jingzhao venom gland. Toxicon 52(7), 794-806 (2008).
35. Tang X, Zhang Y, Hu W et al. Molecular diversification of peptide toxins from the tarantula Haplopelma hainanum (Ornithoctonus hainana) venom based on transcriptomic, peptidomic, and genomic analyses. J. Proteome Res. 9(5), 2550-2564 (2010).
36. Jiang L, Chen J, Peng L, Zhang Y, Xiong X, Liang S. Genomic organization and cloning of novel genes encoding toxin-like peptides of three superfamilies from the spider Orinithoctonus huwena. Peptides 29(10), 1679-1684 (2008).
37. Gremski LH, da Silveira RB, Chaim OM et al. A novel expression profile of the Loxosceles intermedia spider venomous gland revealed by transcriptome analysis. Mol. Biosyst. 6(12), 2403-2416 (2010).
38. Fernandes-Pedrosa MdF, Junqueira-de-Azevedo IdLM, Goncalves-de-Andrade RM et al. Transcriptome analysis of Loxosceles laeta (Araneae, Sicariidae) spider venomous gland using expressed sequence tags. BMC Genomics 9, 279 (2008).
39. Zhang Y, Chen J, Tang X et al. Transcriptome analysis of the venom glands of the Chinese wolf spider Lycosa singoriensis. Zoology 113(1), 10-18 (2010).
40. Diego-Garcia E, Peigneur S, Waelkens E, Debaveye S, Tytgat J. Venom components from Citharischius crawshayi spider (Family Theraphosidae): exploring transcriptome, venomics, and function. Cell. Mol. Life Sci. 67(16), 2799-2813 (2010).
41. Wong ES, Hardy MC, Wood D, Bailey T, King GF. SVM-based prediction of propeptide cleavage sites in spider toxins identifies toxin innovation in an Australian tarantula. PLoS ONE 8(7), e66279 (2013).
42. Undheim EA, Sunagar K, Herzig V et al. A proteomics and transcriptomics investigation of the venom from the barychelid spider Trittame loki (brush-foot trapdoor). Toxins 5(12), 2488-2503 (2013).
43. He Q, Duan Z, Yu Y, Liu Z, Liu Z, Liang S. The venom gland transcriptome of Latrodectus tredecimguttatus revealed by deep sequencing and cDNA library analysis. PLoS ONE 8(11), e81357 (2013).
44. Sanggaard KW, Bechsgaard JS, Fang X et al. Spider genomes provide insight into composition and evolution of venom and silk. Nat. Commun. 5, 3765 (2014).
45. Gregory TR, Shorthouse DP. Genome sizes of spiders. J. Heredity 94, 285-290 (2003).
46. Davis J, Jones A, Lewis RJ. Remarkable inter- and intra-species complexity of conotoxins revealed by LC/MS. Peptides 30(7), 1222-1227 (2009).
47. Bandeira N, Clauser KR, Pevzner PA. Shotgun protein sequencing: assembly of peptide tandem mass spectra from mixtures of modified proteins. Mol. Cell. Proteomics 6(7), 1123-1134 (2007).
48. Ueberheide BM, Fenyo D, Alewood PF, Chait BT. Rapid sensitive analysis of cysteine rich peptide venom components. Proc. Natl Acad. Sci. USA 106(17), 6910-6915 (2009).
49. Perkins DN, Pappin DJC, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20(18), 3551-3567 (1999).
50. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 20(9), 1466-1467 (2004).
51. Zobel-Thropp PA, Correa SM, Garb JE, Binford GJ. Spit and venom from Scytodes spiders: a diverse and distinct cocktail. J. Proteome Res. 13(2), 817-835 (2013).
52. Duan Z, Cao R, Jiang L, Liang S. A combined de novo protein sequencing and cDNA library approach to the venomic analysis of Chinese spider A raneus ventricosus. J. Proteomics 78, 416-427 (2013).
53. Craik DJ, Adams DJ. Chemical modification of conotoxins to improve stability and activity. ACS Chem. Biol. 2(7), 457-468 (2007).
54. Muttenthaler M, Akondi KB, Alewood PF. Structure-activity studies on α-conotoxins. Curr. Pharm. Des. 17(38), 4226-4241 (2011).
55. Revell JD, Lund PE, Linley JE et al. Potency optimization of huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena. Peptides 44, 40-46 (2013).
56. Dawson PE, Muir TW, Clark-Lewis I, Kent SBH. Synthesis by native chemical ligation. Science 266, 776-779 (1994).
57. Jensen JE, Durek T, Alewood PF, Adams DJ, King GF, Rash LD. Chemical synthesis and folding of APETx2, a potent and selective inhibitor of acid sensing ion channel 3. Toxicon 54(1), 56-61 (2009).
58. Durek T, Vetter I, Wang C-IA et al. Chemical engineering and structural and pharmacological characterization of the α-scorpion toxin OD1. ACS Chem. Biol. 8(6), 1215-1222 (2013).
59. Schroeder CI, Rash LD, Vila-Farrés X et al. Chemical synthesis, 3D structure, and ASIC binding site of the toxin mambalgin-2. Angew. Chem. Int. Ed. 53(4), 1017-1020 (2014).
60. Bulaj G, Olivera BM. Folding of conotoxins: formation of the native disulfide bridges during chemical synthesis and biosynthesis of Conus peptides. Antioxid. Redox Signal. 10(1), 141-155 (2008).
61. Anangi R, Chen C-Y, Cheng C-H et al. Expression of snake venom toxins in Pichia pastoris. Toxin Rev. 26, 169-187 (2007).
62. Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60(3), 512-538 (1996).
63. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotech. 22(11), 1399-1408 (2004).
64. Tedford HW, Fletcher JI, King GF. Functional significance of the β-hairpin in the insecticidal neurotoxin ω-atracotoxin-Hv1a. J. Biol. Chem. 276, 26568-26576 (2001).
65. Klint JK, Senff S, Saez NJ et al. Production of recombinant disulfide-rich venom peptides for structural and functional analysis via expression in the periplasm of E. coli. PLoS ONE 8(5), e63865 (2013).
66. Ito K, Inaba K. The disulfide bond formation (Dsb) system. Curr. Opin. Struct. Biol. 18(4), 450-458 (2008).
67. Heras B, Shouldice SR, Totsika M, Scanlon MJ, Schembri MA, Martin JL. DSB proteins and bacterial pathogenicity. Nat. Rev. Microbiol. 7(3), 215-225 (2009).
68. Kwan AH, Mobli M, Gooley PR, King GF, Mackay JP. Macromolecular NMR spectroscopy for the non-spectroscopist. FEBS J. 278(5), 687-703 (2011).
69. Dawson RJ, Benz J, Stohler P et al. Structure of the acid-sensing ion channel 1 in complex with the gating modifier psalmotoxin 1. Nat. Commun. 3, 936 (2012).
70. Baconguis I, Gouaux E. Structural plasticity and dynamic selectivity of acid-sensing ion channel-spider toxin complexes. Nature 489(7416), 400-405 (2012).
71. Cao E, Liao M, Cheng Y, Julius D. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504(7478), 113-118 (2013).
72. Mobli M, Maciejewski MW, Gryk MR, Hoch JC. An automated tool for maximum entropy reconstruction of biomolecular NMR spectra. Nat. Methods 4(6), 467-468 (2007).
73. Mobli M, Stern AS, Bermel W, King GF, Hoch JC. A non-uniformly sampled 4D HCC(CO)NH-TOCSY experiment processed using maximum entropy for rapid protein sidechain assignment. J. Magn. Reson. 204, 160-164 (2010).
74. Güntert P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 278, 353-378 (2004).
75. Saez NJ, Mobli M, Bieri M et al. A dynamic pharmacophore drives the interaction between psalmotoxin-1 and the putative drug target acid-sensing ion channel 1a. Mol. Pharmacol. 80, 796-808 (2011).
76. Bende NS, Kang E, Herzig V et al. The insecticidal neurotoxin Aps III is an atypical knottin peptide that potently blocks insect voltage-gated sodium channels. Biochem. Pharmacol. 85(10), 1542-1554 (2013).
77. Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244(4908), 1081-1085 (1989).
78. Maggio F, King GF. Scanning mutagenesis of a Janus-faced atracotoxin reveals a bipartite surface patch that is essential for neurotoxic function. J. Biol. Chem. 277, 22806-22813 (2002).
79. Tedford HW, Gilles N, Ménez A, Doering CJ, Zamponi GW, King GF. Scanning mutagenesis of ω-atracotoxin-Hv1a reveals a spatially restricted epitope that confers selective activity against invertebrate calcium channels. J. Biol. Chem. 279, 44133-44140 (2004).
80. Corzo G, Sabo JK, Bosmans F et al. Solution structure and alanine scan of a spider toxin that affects the activation of mammalian voltage-gated sodium channels. J. Biol. Chem. 282(7), 4643-4652 (2007).
81. Estrada G, Villegas E, Corzo G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat. Prod. Rep. 24(1), 145-161 (2007).
82. Windley MJ, Herzig V, Dziemborowicz SA, Hardy MC, King GF, Nicholson GM. Spider-venom peptides as bioinsecticides. Toxins 4(3), 191-227 (2012).
83. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57(4), 397-409 (2005).
84. Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 4, 207 (2003).
85. V channels. Channels 2(2), 100-116 (2008).
86. Waxman SG, Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol. Med. 11(12), 555-562 (2005).
87. Rush AM, Dib-Hajj SD, Liu SJ, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyperor hypoexcitability in different types of neurons. Proc. Natl Acad. Sci. USA 103, 8245-8250 (2006).
88. v1.7 cause moderate destabilization of fast inactivation. J. Physiol. 586(17), 4137-4153 (2008).
89. Cox JJ, Reimann F, Nicholas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444(7121), 894-898 (2006).
90. Weiss J, Pyrski M, Jacobi E et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature 472(7342), 186-190 (2011).
91. V1.7 in the normal and injured rodent olfactory system indicates a critical role in olfaction, pheromone sensing and immune function. Channels 6, 103-110 (2012).
92. Reimann F, Cox JJ, Belfer I et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc. Natl Acad. Sci. USA 107(11), 5148-5153 (2010).
93. Duan G, Xiang G, Zhang X, Yuan R, Zhan H, Qi D. A single-nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in the general population. Anesthesiology 118, 436-442 (2013).
94. Clare JJ. Targeting voltage-gated sodium channels for pain therapy. Expert Opin. Investig. Drugs 19(1), 45-62 (2010).
95. + channel modulators as next-generation analgesics. Future Med. Chem. 2(5), 775-790 (2010).
96. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26(1), 13-25 (2000).
97. Krafte DS, Bannon AW. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 8(1), 50-56 (2008).
98. Klint JK, Senff S, Rupasinghe DB et al. Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. Toxicon 60(4), 478-491 (2012).
99. V1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 74(5), 1476-1484 (2008).
100. Bosmans F, Rash L, Zhu SY et al. Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. Mol. Pharmacol. 69(2), 419-429 (2006).
101. Ono S, Kimura T, Kubo T. Characterization of voltage-dependent calcium channel blocking peptides from the venom of the tarantula Grammostola rosea. Toxicon 58(3), 265-276 (2011).
102. King GF, Gentz MC, Escoubas P, Nicholson GM. A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 52(2), 264-276 (2008).
103. ArachnoServer. www.arachnoserver.org/
104. V channels by peptidic spider toxins. Toxicon 49(4), 513-530 (2007).
105. 2+ channels to treat pain: T-type versus N-type. Trends Pharmacol. Sci. 25(9), 465-470 (2004).
106. McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr. Drug Targets CNS Neurol. Disord. 3(6), 457-478 (2004).
107. Deng M, Luo X, Xiao Y et al. Huwentoxin-XVI, an analgesic, highly reversible mammalian N-type calcium channel antagonist from Chinese tarantula Ornithoctonus huwena. Neuropharmacology 79, 657-667 (2014).
108. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11(23), 3029-3040 (2004).
109. McNamara CR, Mandel-Brehm J, Bautista DM et al. TRPA1 mediates formalin-induced pain. Proc. Natl Acad. Sci. USA 104(33), 13525-13530 (2007).
110. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol. Rev. 64(2), 259-298 (2012).
111. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol. Rev. 82(3), 735-767 (2002).
112. Lingueglia E. Acid-sensing ion channels in sensory perception. J. Biol. Chem. 282(24), 17325-17329 (2007).
113. Sluka KA, Winter OC, Wemmie JA. Acid-sensing ion channels: a new target for pain and CNS diseases. Curr. Opin. Drug Discov. Dev. 12(5), 693-704 (2009).
114. Voilley N. Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr. Drug Targets Inflamm. Allergy 3(1), 71-79 (2004).
115. Gwanyanya A, Macianskiene R, Mubagwa K. Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. J. Pharm. Pharmacol. 64(10), 1359-1375 (2012).
116. + channels. J. Biol. Chem. 275(33), 25116-25121 (2000).
117. Mazzuca M, Heurteaux C, Alloui A et al. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat. Neurosci. 10(8), 943-945 (2007).
118. Smith HS. Intrathecal drug delivery. Pain Physician 11, S89-S104 (2008).
119. Tedford HW, Steinbaugh BA, Bao L et al. In silico screening for compounds that match the pharmacophore of ω-hexatoxin-Hv1a leads to discovery and optimization of a novel class of insecticides. Pesticide Biochem. Physiol. 106, 124-140 (2013).
120. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 67(2), 181-198 (2010).
121. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol. Neurodegener. 6(1), 11 (2011).
122. Liu R, Yuan H, Yuan F, Yang SH. Neuroprotection targeting ischemic penumbra and beyond for the treatment of ischemic stroke. Neurol. Res. 34(4), 331-337 (2012).
123. Xiong ZG, Chu XP, Simon RP. Acid sensing ion channels - novel therapeutic targets for ischemic brain injury. Front. Biosci. 12, 1376-1386 (2007).
124. Xiong ZG, Zhu XM, Chu XP et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118(6), 687-698 (2004).
125. Isaev NK, Stelmashook EV, Plotnikov EY et al. Role of acidosis, NMDA receptors, and acid-sensitive ion channel 1a (ASIC1a) in neuronal death induced by ischemia. Biochemistry (Moscow) 73(11), 1171-1175 (2008).
126. Leng TD, Xiong ZG. The pharmacology and therapeutic potential of small molecule inhibitors of acid-sensing ion channels in stroke intervention. Acta Pharmacol. Sin. 34(1), 33-38 (2013).
127. Pignataro G, Simon RP, Xiong ZG. Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia. Brain 130, 151-158 (2007).
128. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1(6), 383-386 (2002).
129. 7 purinergic receptor: from physiology to neurological disorders. FASEB J. 24(2), 337-345 (2010).
130. 3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 17(11), 3016-3028 (1998).
131. 2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl Acad. Sci. USA 99(26), 17179-17184 (2002).
132. 3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol. Pharmacol. 69(6), 2058-2067 (2006).
133. 3 receptor antagonist. J. Med. Chem. 50(18), 4543-4547 (2007).
134. Grishin EV, Savchenko GA, Vassilevski AA et al. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain. Ann. Neurol. 67(5), 680-683 (2010).
135. Cohen E, Quistad GB. Cytotoxic effects of arthropod venoms on various cultured cells. Toxicon 36(2), 353-358 (1998).
136. Gao L, Shan BE, Chen J, Liu JH, Song DX, Zhu BC. Effects of spider Macrothele raven venom on cell proliferation and cytotoxicity in HeLa cells. Acta Pharmacol. Sin. 26(3), 369-376 (2005).
137. Gao L, Yu S, Wu Y, Shan B. Effect of spider venom on cell apoptosis and necrosis rates in MCF-7 cells. DNA Cell Biol. 26, 485-489 (2007).
138. Liu Z, Zhao Y, Li J et al. The venom of the spider Macrothele raveni induces apoptosis in the myelogenous leukemia K562 cell line. Leuk. Res. 36(8), 1063-1066 (2012).
139. + channels by Psalmotoxin 1. Am. J. Physiol. Cell Physiol. 287, C1282-C1291 (2004).
140. Li M, Inoue K, Branigan D et al. Acid-sensing ion channels in acidosis-induced injury of human brain neurons. J. Cereb. Blood Flow Metab. 30(6), 1247-1260 (2010).
141. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 278(6), 4135-4144 (2003).
142. Kesavan K, Ratliff J, Johnson EW et al. Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J. Biol. Chem. 285(7), 4366-4374 (2010).
143. Veiseh M, Gabikian P, Bahrami SB et al. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 67(14), 6882-6888 (2007).
144. Stroud MR, Hansen SJ, Olson JM. In vivo bio-imaging using chlorotoxin-based conjugates. Curr. Pharm. Des. 17(38), 4362-4371 (2011).